Substance / Medication

Omeprazole

Overview

Active Ingredient
omeprazole
RxNorm CUI
7646
Labeler: PD-Rx Pharmaceuticals, Inc.Updated: 2026-02-25T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

5.2 (6) • Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubul

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

54 trials linked to this intervention

54
Total Trials
7
Recruiting
23
With Results

Research Evidence

Published studies and systematic reviews

Sort:
[Omeprazole of limited value in crying babies].
Blokpoel Robert G T, Broos Nancy, de Jong-van den Berg Lolkje T W et al. · Ned Tijdschr Geneeskd · 2010
PMID: 20719016Meta-Analysis
The effect of the use of omeprazole versus famotidine on the kidney transplant function: a randomized controlled study.
Miedziaszczyk Miłosz, Karczewski Marek, Idasiak-Piechocka Ilona · Sci Rep · 2025
PMID: 39805983RCTFull text (PMC)
Oral omeprazole and diclofenac intake is associated with increased faecal calprotectin levels: a randomised open-label clinical trial.
Rendek Zlatica, Falk Magnus, Grodzinsky Ewa et al. · Eur J Gastroenterol Hepatol · 2023
PMID: 36468569RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Omeprazole (substance)
SNOMED CT
387137007
UMLS CUI
C0028978
RxNorm CUI
7646
Labeler
PD-Rx Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
54
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.